CRB Digital Health III is the first European fund fully dedicated to digital health based in Spain. It is managed by CRB Health Tech, S.G.E.I.C., S.A. (with offices in Madrid and Barcelona) and focuse...
New LPs include BBVA Spark, one of the founding families of Mahou, the family office of Javier de Jaime, Managing Partner at CVC, and José de Mello Capital. Long-standing partners such as CDTI Innvie...
The funds will be used to incorporate new advances into the FiCAT gene writing platform, validate various next generation CAR-T therapies in the preclinical phase and expand the FiCAT cell engineering...
Basquevolt’s technology focuses on manufacturing cells for electric vehicles, stationary energy storage, hydrogen and gas hybridization, as well as advanced portable electronic devices. In this cont...
Founded in 2018, Pangea Aerospace is based in Barcelona and Toulouse, specializing in the development of advanced propulsion technologies for the space industry. Its innovative propulsion systems enab...
Since its founding in 2019, VEGA Chargers has experienced rapid growth, positioning itself as a key player in the fast and ultra-fast charging sector. Its technological solutions have been implemented...
Los fondos aportados por CDTI INNVIERTE y NARA CAPITAL combinado con financiación pública y privada adicional, permitirán a la compañía avanzar en los estudios clínicos necesarios para llevar he...
La ronda, de un total de 30 M€, incluye venture debt y private equity. Participan, además de Innvierte, GPC, Banco de Santander y Sodical Instituto Financiero de Castilla y León. La compañía bio...
El CDTI Innovación, promotor y accionista único de la sociedad Innvierte, ha cerrado 8 operaciones durante el mes de mayo, por importe de 6.108.000 euros. Desde enero de 2024 se han cerrado operacio...
La empresa ha patentado un diseño de caldera solar que consigue temperaturas de hasta 450ºC. El calor generado se utiliza para generar el vapor que demanda la mayoría de procesos industriales. Mult...
The Catalan biopharmaceutical company Ability Pharmaceuticals, SA (AbilityPharma), focused on the development of innovative oral autophagy-inducing anticancer compounds, announces a €7M investment f...
The substantial investment will drive the development of the company's groundbreaking gynecological diagnostics solutions, with key EU participation from the EIC Accelerator (European Innovation Counc...